NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MTVA

MetaVia Inc

Jul 01 • 04:00PM ET

0.6500

Dollar change +0.0068
Percentage change 1.06	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF DFAS DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.36	Insider Own	64.31%	Shs Outstand	8.65M	Perf Week	-3.19%
Market Cap	12.73M	Forward P/E	-	EPS next Y	-1.10	Insider Trans	58.76%	Shs Float	6.99M	Perf Month	-0.03%
Enterprise Value	1.66M	PEG	-	EPS next Q	-0.24	Inst Own	3.64%	Short Float	2.45%	Perf Quarter	-57.79%
Income	-24.55M	P/S	-	EPS this Y	68.96%	Inst Trans	3.46%	Short Ratio	0.24	Perf Half Y	-64.09%
Sales	0.00M	P/B	1.28	EPS next Y	0.23%	ROA	-168.46%	Short Interest	0.17M	Perf YTD	-67.98%
Book/sh	0.51	P/C	1.14	EPS next 5Y	26.17%	ROE	-339.64%	52W High	5.16 -87.40%	Perf Year	-86.46%
Cash/sh	0.57	P/FCF	-	EPS past 3/5Y	71.79% 67.49%	ROIC	-555.78%	52W Low	0.63 3.17%	Perf 3Y	-99.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.46% 5.88%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-3.04%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.36	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	72.89%	SMA20	-6.42%	Beta	0.21	Target Price	13.75
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-9.97%	Rel Volume	0.06	Prev Close	0.64
Employees	9	LT Debt/Eq	0.01	Earnings	May 14 AMC	SMA200	-63.70%	Avg Volume	703.85K	Price	0.65
IPO	Aug 05, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	7.69% -	Trades		Volume	40,566	Change	1.06%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$12

Jun-21-25 09:00AM	MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session (PR Newswire)
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire)
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire) +7.73%
08:31AM	MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th (GlobeNewswire)
Jun-04-25 08:31AM	MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions (PR Newswire)
07:00AM	Loading…
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-14-25 04:05PM	MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-09-25 08:01AM	MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (PR Newswire)
May-07-25 02:00AM	MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 (PR Newswire) -8.05%
Apr-23-25 08:31AM	MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 (PR Newswire) +8.40%
Apr-22-25 08:31AM	MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential (PR Newswire)
Apr-15-25 07:01AM	MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability (PR Newswire) -55.98%
Mar-20-25 07:31AM	MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jan-10-25 08:05AM	MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference (PR Newswire)
Dec-19-24 08:01AM	MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire)
08:01AM	Loading…
Dec-18-24 08:01AM	MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire) -17.73%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 08:01AM	MetaVia to Present at the Emerging Growth Conference in December (PR Newswire)

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Woodworth Marshall H	Chief Financial Officer	Jun 04 '25	Buy	0.70	14,200	9,940	44,279	Jun 04 04:01 PM
DONG-A ST CO., LTD	10% Owner	May 08 '25	Buy	0.71	4,647,887	3,300,000	9,995,679	May 20 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTVA

MetaVia Inc

Upgrade your FINVIZ experience